Guobang Pharma Ltd. (SHA:605507)
China
· Delayed Price · Currency is CNY 24.22
+0.36 (1.51%)
Apr 29, 2026, 3:00 PM CST
Guobang Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 6,068 | 5,988 | 5,867 | 5,327 | 5,704 | 4,493 | Upgrade
|
| Other Revenue | 23.8 | 23.8 | 23.85 | 22.35 | 17.33 | 12.43 | Upgrade
|
| Revenue | 6,092 | 6,011 | 5,891 | 5,349 | 5,721 | 4,505 | Upgrade
|
| Revenue Growth (YoY) | 1.67% | 2.05% | 10.12% | -6.49% | 26.98% | 7.11% | Upgrade
|
| Cost of Revenue | 4,594 | 4,483 | 4,455 | 4,141 | 4,190 | 3,212 | Upgrade
|
| Gross Profit | 1,499 | 1,528 | 1,435 | 1,209 | 1,531 | 1,294 | Upgrade
|
| Selling, General & Admin | 361.69 | 366.34 | 345.57 | 365.25 | 339.93 | 297.29 | Upgrade
|
| Research & Development | 200.82 | 209.83 | 215.05 | 190.51 | 197.54 | 155.27 | Upgrade
|
| Other Operating Expenses | 39.03 | 32.27 | 26.73 | 30.96 | 31.9 | 23.67 | Upgrade
|
| Operating Expenses | 609.74 | 614.1 | 599.43 | 579.55 | 581.08 | 478.27 | Upgrade
|
| Operating Income | 888.78 | 914.38 | 835.91 | 629.3 | 949.97 | 815.55 | Upgrade
|
| Interest Expense | -27.49 | -23.92 | -27.28 | -22.58 | -16.55 | -28.72 | Upgrade
|
| Interest & Investment Income | 31.54 | 34.56 | 42.89 | 65 | 48.9 | 22.66 | Upgrade
|
| Currency Exchange Gain (Loss) | -9.17 | -9.17 | 32.46 | 22.04 | 58.72 | -14.48 | Upgrade
|
| Other Non Operating Income (Expenses) | -25.91 | -4.42 | -5.48 | -7.41 | -4.31 | -2.13 | Upgrade
|
| EBT Excluding Unusual Items | 857.74 | 911.43 | 878.5 | 686.35 | 1,037 | 792.88 | Upgrade
|
| Gain (Loss) on Sale of Investments | 13.12 | 12.92 | 14.4 | 10.34 | 4.56 | 6.26 | Upgrade
|
| Gain (Loss) on Sale of Assets | 24.1 | 24.81 | -9.11 | 0.72 | -15.84 | 0.3 | Upgrade
|
| Asset Writedown | -15.06 | -7.67 | -6.54 | -5.8 | -0.05 | -9.31 | Upgrade
|
| Other Unusual Items | 9.7 | 9.76 | 10.71 | 6.04 | 10.24 | 16.65 | Upgrade
|
| Pretax Income | 889.6 | 951.26 | 887.97 | 697.65 | 1,036 | 806.78 | Upgrade
|
| Income Tax Expense | 126.16 | 133.69 | 107.39 | 87.67 | 115.02 | 100.55 | Upgrade
|
| Earnings From Continuing Operations | 763.44 | 817.57 | 780.58 | 609.98 | 920.62 | 706.23 | Upgrade
|
| Minority Interest in Earnings | 3.03 | 3.25 | 1.02 | 2.49 | 0.28 | -0.2 | Upgrade
|
| Net Income | 766.47 | 820.82 | 781.6 | 612.46 | 920.9 | 706.03 | Upgrade
|
| Net Income to Common | 766.47 | 820.82 | 781.6 | 612.46 | 920.9 | 706.03 | Upgrade
|
| Net Income Growth | -3.93% | 5.02% | 27.62% | -33.49% | 30.43% | -12.84% | Upgrade
|
| Shares Outstanding (Basic) | 552 | 555 | 558 | 557 | 558 | 512 | Upgrade
|
| Shares Outstanding (Diluted) | 552 | 555 | 558 | 557 | 558 | 512 | Upgrade
|
| Shares Change (YoY) | -1.79% | -0.66% | 0.27% | -0.24% | 9.09% | 8.01% | Upgrade
|
| EPS (Basic) | 1.39 | 1.48 | 1.40 | 1.10 | 1.65 | 1.38 | Upgrade
|
| EPS (Diluted) | 1.39 | 1.48 | 1.40 | 1.10 | 1.65 | 1.38 | Upgrade
|
| EPS Growth | -2.18% | 5.71% | 27.27% | -33.33% | 19.56% | -19.30% | Upgrade
|
| Free Cash Flow | 776.02 | 281.57 | 287.29 | -231.68 | 213.92 | -624.23 | Upgrade
|
| Free Cash Flow Per Share | 1.41 | 0.51 | 0.52 | -0.42 | 0.38 | -1.22 | Upgrade
|
| Dividend Per Share | 0.600 | 0.600 | 0.606 | 0.302 | 0.600 | 0.700 | Upgrade
|
| Dividend Growth | -0.96% | -0.96% | 100.92% | -49.74% | -14.29% | - | Upgrade
|
| Gross Margin | 24.60% | 25.43% | 24.37% | 22.60% | 26.76% | 28.72% | Upgrade
|
| Operating Margin | 14.59% | 15.21% | 14.19% | 11.76% | 16.61% | 18.10% | Upgrade
|
| Profit Margin | 12.58% | 13.65% | 13.27% | 11.45% | 16.10% | 15.67% | Upgrade
|
| Free Cash Flow Margin | 12.74% | 4.68% | 4.88% | -4.33% | 3.74% | -13.86% | Upgrade
|
| EBITDA | 1,377 | 1,391 | 1,269 | 950.43 | 1,210 | 1,016 | Upgrade
|
| EBITDA Margin | 22.60% | 23.14% | 21.55% | 17.77% | 21.15% | 22.56% | Upgrade
|
| D&A For EBITDA | 487.86 | 476.96 | 433.38 | 321.14 | 260.21 | 200.9 | Upgrade
|
| EBIT | 888.78 | 914.38 | 835.91 | 629.3 | 949.97 | 815.55 | Upgrade
|
| EBIT Margin | 14.59% | 15.21% | 14.19% | 11.76% | 16.61% | 18.10% | Upgrade
|
| Effective Tax Rate | 14.18% | 14.05% | 12.09% | 12.57% | 11.11% | 12.46% | Upgrade
|
| Revenue as Reported | 6,092 | 6,011 | 5,891 | 5,349 | 5,721 | 4,505 | Upgrade
|
| Advertising Expenses | - | 2.66 | 1.94 | 1.52 | 3.42 | 1.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.